Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) reports no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug
- As part of the trial, 10 healthy male subjects were dosed for over an hour, with the 6000-milligram dose marking a 120-fold increase on the first cohort of the trial
- The latest trial data is now being reviewed by an Independent Safety Committee, which is expected to give Recce the green light to move forward and dose Cohort Eight with R327
- The company says it has begun preparations for the next phase of the trial
- Shares in Recce Pharmaceuticals last traded at 85.5 cents each on August 19
Recce Pharmaceuticals (RCE) has reported no serious adverse effects from intravenously dosing the seventh cohort of its phase one clinical trial with 6000 milligrams of its R327 drug.
As part of the trial, 10 healthy male subjects were dosed for over an hour, with the 6000-milligram dose marking a 120-fold increase on the first cohort of the trial, which received 50 milligrams of the treatment.
The latest trial data is now being reviewed by an Independent Safety Committee, which is expected to give Recce the green light to move forward and dose the eighth trial cohort with R327.
The company said it had begun preparations for the next phase of the trial.
CEO James Graham said he was “thrilled” to complete the round of dosing.
“Achieving a 120-fold increase from Cohort One, with anticipation to soon begin a Cohort Eight, continues to build the safety and tolerability profile as a potential new class of antiinfectives,” he said.
R327 is designed to treat serious bacterial infections including sepsis.
The company said the 6000-milligram dose was broadly in the efficacy range of the treatment based on previous animal models.
Shares in Recce Pharmaceuticals last traded at 85.5 cents each on August 19.
